Global Information
회사소개 | 문의 | 비교리스트

세계의 암치료용 사이클린 의존성 키나아제(CDK) 저해제 시장 : 임상 파이프라인 전망

Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022

리서치사 KuicK Research
발행일 2017년 11월 상품 코드 577294
페이지 정보 영문 150 Pages
US $ 2,200 ₩ 2,658,000 Unprintable PDF by E-mail (Single User License)
US $ 3,000 ₩ 3,625,000 CD-ROM
US $ 3,600 ₩ 4,350,000 Hard Copy
US $ 4,000 ₩ 4,834,000 Printable PDF by E-mail (Multi-User License)

세계의 암치료용 사이클린 의존성 키나아제(CDK) 저해제 시장 : 임상 파이프라인 전망 Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022
발행일 : 2017년 11월 페이지 정보 : 영문 150 Pages

세계의 사이클린 의존성 키나아제(CDK) 저해제 시장에 대해 조사했으며, 암치료용 CDK 저해제 개요와 중요성, 작용기전, 적응 질환, 임상 파이프라인의 유망 후보의약품, 가격 비교 분석, 성장 촉진요인 및 저해요인 분석, 기업·단계별 임상시험 동향, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 CDK 저해제 : 유망한 암 치료제

  • CDK 치료제 개발까지의 역사
  • 세포 주기, 사이클린, CDK의 역할
  • 암치료용 CDK 저해제: 개요

제2장 사이클린 의존성 키나아제(CDK) : 암치료에서의 표적

  • CDK 경로 & 세포 주기 체크포인트
  • 발암에서 사이클린 의존성 키나아제의 역할
  • 암과 CDK의 관련성

제3장 CDK 저해제의 적응 질환과 작용기전

제4장 CDK 저해제의 종류

  • ATP Competitive CDK Inhibitors
  • ATP Non Competitive Inhibitors
  • Allosteric Inhibitors

제5장 CDK 관련 암 치료제의 최신 동향

  • 유방암에서의 CDK4/6
  • 혈액악성종양에서 CDK의 역할

제6장 병용 치료제로서의 CDK 저해제

제7장 CDK 저해제 시장 개요

  • CDK 저해제의 상업적 측면
  • CDK 저해제 주요 기업
  • CDK 저해제 파이프라인 개요

제8장 출시된 CDK 저해제의 임상시험 동향

  • Palbociclib (Ibrance)
  • Ribociclib (Kisqali)

제9장 CDK 저해제 가격 분석

  • 출시된 CDK 저해제 가격 분석
  • CDK 저해제와 기타 암 치료제 비교

제10장 시장 성장 촉진요인

  • Ibrance의 신속 승인
  • 암 이환률 상승
  • 임상 파이프라인
  • 연구개발 진전
  • 미개척 의료 요구

제11장 시장 성장 저해요인

  • CDK 저해제의 높은 비용
  • 과학 및 기술적 제약
  • 부작용과 유효성
  • 기타 암 치료제와의 경쟁
  • 치료제 인증까지의 기간
  • 상업상 과제

제12장 CDK 저해제 시장에 대한 기대

제13장 CDK 저해제 임상시험 동향 : 기업 및 임상시험 단계별

  • 전임상
  • 제1상
  • 제1/2상
  • 제2상
  • 제3상
  • 예비등록

제14장 경쟁 구도

  • Amgen
  • Anygen
  • Astex
  • Bayer Pharmaceuticals
  • BioCAD
  • Cyclacel
  • Eli Lilly
  • G1 Therapeutics
  • Nerviano Medical Science
  • Merck
  • Pfizer
  • Piramal Life
  • Syros Pharmaceuticals
  • Sanofi-Aventis
LSH 17.11.24

"Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment of cancer and more than 45 CDK inhibitors are in various phases of clinical pipeline.

"Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report highlights:

  • Selectivity & Working Mechanism of a Cancer CDKs Inhibitor
  • Recent Advances in the CDKs Related Cancer Therapy
  • Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
  • Market Opportunity Assessment: More Than US$ 20 Billion (2022)
  • Price Analysis of Cancer CDKs Inhibitors:
  • Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)

The Cyclin Dependent Kinase (CDK) Inhibitors have recently emerged as one of the most promising therapeutics in the cancer pharmaceuticals segment. The progress in the scientific and technical knowledge of how the cell cycle works, pathways involved in normal and tumorous cells and the role of cyclin in tumor cell formation (Tumorigenesis) has led to an excellent boost in the research and development of special molecules or inhibitors which can prevent tumorigenic processes in effected cells.

Cyclin Dependent Kinase (CDK) Inhibitors are considered as promising and immensely effective targeted therapy of the future as it aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body. In addition, it has opened up multiple opportunities and avenues for the life sciences industry to work upon due to the vast diversity and variations seen in the CDK pathways and their specific role and response in various types of tumors, thus suggesting the need of different types of inhibitors for different cancer therapies.

Currently, Pfizer's Ibrance is the only successfully market drug that has shown impressive growth in within two years of its introduction into the cancer therapy segment. Ibrance or Palbociclib first received an accelerated approval in February 2015, becoming the first CDKs inhibitor to receive approval for breast cancer therapy. In just two years Ibrance has shown excellent growth with time which is sure to make Ibrance the dominant CDKs inhibitor in the breast cancer therapy segment.

The recent advances in the discovery of newer cyclin pathways and their inhibitors have opened up new avenues in the CDKs therapy market. Multiple companies are now currently working on various therapeutics that have shown some kind of novel response in stopping or inhibiting the cell cycle. While it is obvious that Pfizer's Ibrance is currently the most effective drug in breast cancer tumor management, it is expected that Eli Lilly and Novartis are currently working on much better therapeutic having higher overall efficacy than the Ibrance.

A strong clinical pipeline presents an encouraging scenario regarding the future of a particular therapeutic like the CDK inhibitor. The intense research and development in the CDK inhibitor segment has led to many of these newly discovered compounds showing excellent results in various phase of the clinical trials. While very few CDKs have come out of the clinical pipeline and showed excellent commercial success, many of the inhibitors are anticipated to be a blockbuster drug once they come out of the clinical pipeline.

With the advancement in science and further knowledge about the technical know-how of the cyclin dependent kinase and cell cycle, the ability and potential of CDKs inhibitor as cancer therapeutic is bound to improve. Previous success of approved CDKs inhibitors like Ibrance has shown the immense market potential of the CDKs inhibitor market which largely remains untapped, especially in the developing countries which are bound to show an increased demand for effective cancer therapeutic like the CDKs in the future.

Table of Contents

1. Cyclin Dependent Kinase Inhibitors -An Introduction to a Promising Cancer Therapeutic

  • 1.1 History of Discoveries Leading to Cyclin Dependent Kinase Inhibitor Drug
  • 1.2 An Insight into Cell Cycle, Cyclin & the Role of CDKs
  • 1.3 Cyclin Dependent Kinase Inhibitors for Cancer - An Overview

2. Cyclin Dependent Kinase Pathway as Targets for Cancer Therapy

  • 2.1 CDK Pathway & Cell Cycle Checkpoints
  • 2.2 Role of Cyclin Dependent Kinases in Carcinogenesis
  • 2.3 Cyclin Dependent Kinases Associated With Various Cancers

3. Selectivity & Working Mechanism of a Cancer CDKs Inhibitor

4. Types of CDK Inhibitors

  • 4.1 ATP Competitive CDK Inhibitors
  • 4.2 ATP Non Competitive Inhibitors
  • 4.3 Allosteric Inhibitors

5. Recent Advances in the CDKs Related Cancer Therapy

  • 5.1 CDK 4/6 in Breast Cancer
  • 5.2 Role of CDKs in Hematological Malignancies

6. CDK Inhibitors as Combinational Cancer Therapeutic

7. Current Market Scenario of Cancer CDKs inhibitors

  • 7.1 Commercial Aspects of CDKs Inhibitor
  • 7.2 Key Market Players in the Cancer CDKs Inhibitor Market
  • 7.3 Global Cancer CDK-Inhibitors Pipeline Overview

8. Marketed Cancer CDK Inhibitors Clinical Insight

  • 8.1 Palbociclib (Ibrance)
  • 8.2 Ribociclib (Kisqali)

9. Price Analysis of Cancer CDKs Inhibitors

  • 9.1 Commercially Available CDK Inhibitors Price Analysis
    • 9.1.1 Cost of Approved Cancer CDKs Inhibitor
    • 9.1.2 Average Cost of CDKs Inhibitors Currently Under Research
  • 9.2 Comparison of Cancer CDKs inhibitor to other Cancer Drugs & Therapies

10. Driving Factors of the Cancer CDKs Inhibitors Market

  • 10.1 Accelerated Approval of Previously Introduced CDKs Inhibitor for Breast Cancer- Ibrance
  • 10.2 Increasing Prevalence of Cancer
  • 10.3 Presence of a Robust Clinical Pipeline
  • 10.4 Advancement in Research & Development
  • 10.5 High Unmet Medical Needs

11. CDK Inhibitors Market Challenges

  • 11.1 High Cost Factor Associated with Cancer CDKs Inhibitor
  • 11.2 Scientific & Technical Limitations
  • 11.3 Side Effects & unreliable Efficacy
  • 11.4 Competition from other Cancer Therapeutic Segments
  • 11.5 Slow FDA Approvals
  • 11.6 Commercial Challenges

12. Anticipation Regarding the Future of CDKs Inhibitor Cancer Therapy Market

13. Global Cancer CDK Inhibitors Clinical Trials Insight by Company, Indication & Phase

  • 13.1 Preclinical
  • 13.2 Phase-I
  • 13.3 Phase-I/II
  • 13.4 Phase-II
  • 13.5 Phase-III
  • 13.6 Preregistration

14. Competitive Landscape

  • 14.1 Amgen
  • 14.2 Anygen
  • 14.3 Astex
  • 14.4 Bayer Pharmaceuticals
  • 14.5 BioCAD
  • 14.6 Cyclacel
  • 14.7 Eli - Lilly
  • 14.8 G1 Therapeutics
  • 14.9 Nerviano Medical Science
  • 14.10 Merck
  • 14.11 Pfizer
  • 14.12 Piramal Life
  • 14.13 Syros Pharmaceuticals
  • 14.14 Sanofi-Aventis
  • Figure 1-1: Timeline Depicting CDK's Development
  • Figure 1-2: Cyclin - The Key Regulators of Cell Cycle
  • Figure 1-3: Cyclin Dependent Kinase and Their cyclin Regulatory Subunits
  • Figure 2-1: Tumor Proliferation Due to Hyperactive Kinase
  • Figure 3-1: Mechanism of Cell Cycle Inhibition by a CDKs Inhibitor
  • Figure 4-1: Allosteric Inhibitors in Action
  • Figure 5-1: Flowchart depicting CDK 4/6 Inhibitor in Action
  • Figure 5-2: CDK 4/6 Inhibition Preventing Tumor Proliferation
  • Figure 7-1: Global - Ibrance CDK Inhibitor Revenue (US$ Billion), 2017
  • Figure 7-2: Global - Cancer CDK Inhibitors Pipeline by Phase (%), 2017 till 2022
  • Figure 7-3: Global - Cancer CDK Inhibitors Pipeline by Phase (Number), 2017 till 2022
  • Figure 7-4: Global - Cancer CDK Inhibitors Pipeline by Phase (%), 2017 till 2022
  • Figure 7-5: Global - Cancer CDK Inhibitors Pipeline by Phase (Number), 2017 till 2022
  • Figure 9-1: Global- Ibrance Revenue (US$ Million), Q1'2015-Q2'2017
  • Figure 9-2: Ibrance- Average Treatment Cost (US$), 2017
  • Figure 9-3: Kisqali - Average Treatment Cost (US$), 2017
  • Figure 9-4: Abemaciclib - Average Treatment Cost (US$), 2017
  • Figure 9-5: Seliciclib- Price Analysis by 10mg, 50mg & 200mg Tablet for CDK5 Inhibitor (US$), 2017
  • Figure 9-6: Dinaciclib - Price Analysis by 5mg, 25mg & 50mg Tablet for CDK1/2, CDK5 & CDK9 Inhibitor (US$), 2017
  • Figure 9-7: SNS-013-Price Analysis by 5mg, 10mg & 50mg Tablet for CDK 7/9/2 Inhibitor (US$), 2017
  • Figure 9-8: Milciclib- Price Analysis by 5mg & 10mg Tablet for CDK 2/7/4/5 Inhibitor (US$), 2017
  • Figure 9-9: Flavopiridol -Price Analysis by 5mg, 25mg & 100mg Tablet for CDK 1/2/4/6 Inhibitor (US$), 2017
  • Figure 9-10: Comparative Price of Approved CDKs Inhibitors (US$/Month), 2017
  • Figure 9-11: Comparative Cost Analysis - Average Price of Existing Breast Cancer Drugs & CDK inhibitors (US$) , 2017
  • Figure 9-12: Comparative Cost Analysis - CDK Inhibitor (Ibrance) & other Targeted Therapy Drugs (US$), 2017
  • Figure 9-13: Comparative Cost Analysis - CDK Inhibitors & Commonly Recommended Cancer Therapeutics (US$), 2017
  • Figure 9-14: Comparative Cost Analysis - CDKs Inhibitor & the Best Available Therapy for Breast Cancer (US$), 2017
  • Figure 10-1: Driving Factors of the Cancer CDKs Inhibitors Market
  • Figure 10-2: Global - Breast Cancer Incidence ('000'), 2015
  • Figure 10-3: Global-Cancer Deaths (%), 2016
  • Figure 11-1: Global - Cancer CDK Inhibitors Market Challenge
  • Figure 12-1: Global- CDKs Inhibitors Market Revenue Forecast (US$ Billion), 2022
  • Figure 12-2: Global - Expected Market Share of CDKs Inhibitor (%), 2022
  • Table 2-1: CDK Aberrations Associated With Various Types of Cancer
  • Table 9-1: Monthly Cost Analysis of Available CDKs Inhibitor for Breast Cancer Therapy
Back to Top
전화 문의